Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 8
2017 17
2018 22
2019 25
2020 12
2021 6
Text availability
Article attribute
Article type
Publication date

Search Results

75 results
Results by year
Filters applied: . Clear all
Page 1
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Perkovic V, et al. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14. N Engl J Med. 2019. PMID: 30990260 Free article. Clinical Trial.
A perspective on chronic kidney disease progression.
Zhong J, Yang HC, Fogo AB. Zhong J, et al. Am J Physiol Renal Physiol. 2017 Mar 1;312(3):F375-F384. doi: 10.1152/ajprenal.00266.2016. Epub 2016 Dec 14. Am J Physiol Renal Physiol. 2017. PMID: 27974318 Free PMC article. Review.
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
Walsh M, Merkel PA, Peh CA, Szpirt WM, Puéchal X, Fujimoto S, Hawley CM, Khalidi N, Floßmann O, Wald R, Girard LP, Levin A, Gregorini G, Harper L, Clark WF, Pagnoux C, Specks U, Smyth L, Tesar V, Ito-Ihara T, de Zoysa JR, Szczeklik W, Flores-Suárez LF, Carette S, Guillevin L, Pusey CD, Casian AL, Brezina B, Mazzetti A, McAlear CA, Broadhurst E, Reidlinger D, Mehta S, Ives N, Jayne DRW; PEXIVAS Investigators. Walsh M, et al. N Engl J Med. 2020 Feb 13;382(7):622-631. doi: 10.1056/NEJMoa1803537. N Engl J Med. 2020. PMID: 32053298 Free PMC article. Clinical Trial.
A reduced-dose regimen of glucocorticoids was noninferior to a standard-dose regimen with respect to death or ESKD. (Funded by the U.K. National Institute for Health Research and others; PEXIVAS Current Controlled Trials number, ISRCTN07757494; ClinicalTrials.gov number, N …
A reduced-dose regimen of glucocorticoids was noninferior to a standard-dose regimen with respect to death or ESKD. (Funded by the U.K. Nati …
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators. Bakris GL, et al. Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25. Am J Nephrol. 2019. PMID: 31655812 Free PMC article. Clinical Trial.
Clinical and histological features and therapeutic strategies for IgA nephropathy.
Moriyama T. Moriyama T. Clin Exp Nephrol. 2019 Sep;23(9):1089-1099. doi: 10.1007/s10157-019-01735-4. Epub 2019 Apr 9. Clin Exp Nephrol. 2019. PMID: 30968243 Review.
In the half century since IgAN was initially reported, our understanding of the long-term prognosis, clinical and histological features, pathogenesis of onset and progression, risk factors for progression, and appropriate treatment under different clinical and histological condit …
In the half century since IgAN was initially reported, our understanding of the long-term prognosis, clinical and histological features, pat …
Modifiable Lifestyle Factors for Primary Prevention of CKD: A Systematic Review and Meta-Analysis.
Kelly JT, Su G, Zhang L, Qin X, Marshall S, González-Ortiz A, Clase CM, Campbell KL, Xu H, Carrero JJ. Kelly JT, et al. J Am Soc Nephrol. 2021 Jan;32(1):239-253. doi: 10.1681/ASN.2020030384. Epub 2020 Aug 31. J Am Soc Nephrol. 2021. PMID: 32868398
CONCLUSIONS: These findings identify modifiable lifestyle factors that consistently predict the incidence of CKD in the community and may inform both public health recommendations and clinical practice....
CONCLUSIONS: These findings identify modifiable lifestyle factors that consistently predict the incidence of CKD in the community and may in …
The Growing Epidemic of Chronic Kidney Disease: Preventive Strategies to Delay the Risk for Progression to ESRD.
Assadi F. Assadi F. Adv Exp Med Biol. 2019;1121:57-59. doi: 10.1007/978-3-030-10616-4_6. Adv Exp Med Biol. 2019. PMID: 31392652 Review.
Considering the high prevalence of hypertension and obesity in children and adolescents and it's risk of progression to cardiovascular disease, CKD should be considered a serious long-term health issue in children with metabolic syndrome. Prevention of CKD requires a profe …
Considering the high prevalence of hypertension and obesity in children and adolescents and it's risk of progression to cardiovascular disea …
Glucose targets for preventing diabetic kidney disease and its progression.
Ruospo M, Saglimbene VM, Palmer SC, De Cosmo S, Pacilli A, Lamacchia O, Cignarelli M, Fioretto P, Vecchio M, Craig JC, Strippoli GF. Ruospo M, et al. Cochrane Database Syst Rev. 2017 Jun 8;6(6):CD010137. doi: 10.1002/14651858.CD010137.pub2. Cochrane Database Syst Rev. 2017. PMID: 28594069 Free PMC article. Review.
75 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page